A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors

NCT04413227 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC
Solid Tumor

Interventions

DRUG: Pegylated Recombinant Human Endostatin（PEG-ENDO）

Sponsor

Jiangsu Simcere Pharmaceutical Co., Ltd.